Clinical trials on trial
By Osagie Obasogie,
The New Scientist
| 01. 22. 2011
[Commentary]
A great deal of scientific research – especially in medicine – relies on human subjects. Protecting volunteers has been a prominent social and legal issue since the 1950s, when the world recoiled from the horrors of Nazi medicine.
We have come a long way since then, but it pays to remember that the Nazis did not have a monopoly on atrocities committed in the name of science. One of the worst cases of human subject abuse was perpetrated by American scientists who, between 1932 and 1972, misled hundreds of black people with syphilis in Tuskegee, Alabama, by deliberately leaving them untreated to enable researchers to study the progression of the disease.
To view the entire article, please click below for version in PDF format.
Related Articles
CGS is excited to announce the launch of a new anti-eugenics initiative that has been years in the making. Legacies of Eugenics in Science, Medicine, and Technology kicks off with a monthly essay series published at the Los Angeles Review of Books that will expose and contest the reemergence of eugenic ideas in contemporary health sciences, human biotechnology, public health, and medicine. Community and campus-based events featuring the authors are also being planned. The project is a collaboration among CGS...
By Jorge Barrera and Rachel Houlihan, CBC | 04.09.2024
A Canadian DNA laboratory knowingly delivered prenatal paternity test results that routinely identified the wrong biological fathers — ruling out the real dads — and left a trail of shattered lives around the globe, a CBC News investigation has found...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...